At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Stephan Stilgenbauer, MD, of Ulm University, Ulm, Germany, reviews the changing chronic lymphocytic leukaemia (CLL) treatment landscape and the progress of optimising new therapeutic approaches for clinical practice.
An update on the treatment of chronic lymphocytic leukaemia
26th August 2015
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?